Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALGeneric

ATROVENT

IPRATROPIUM BROMIDE

Standard Dose
0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ATROVENT is listed in Drugs@FDA under application 020393 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient IPRATROPIUM BROMIDE Form and strength SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2015-05-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview ATROVENT is listed in Drugs@FDA under application 020393 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient IPRATROPIUM BROMIDE Form and strength SPRAY, METERED;NASAL - 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BOEHRINGER INGELHEIM Submission history Latest submission status date: 2015-05-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
ATROVENT (IPRATROPIUM BROMIDE) | Drug Monograph | MedicHelpline